Obispo-Portero, Berta http://orcid.org/0000-0003-1214-6595
Cruz-Castellanos, Patricia http://orcid.org/0000-0002-9837-825X
Jiménez-Fonseca, Paula http://orcid.org/0000-0003-4592-3813
Rogado, Jacobo http://orcid.org/0000-0002-9795-8762
Hernandez, Raquel http://orcid.org/0000-0003-3426-7515
Castillo-Trujillo, Oscar Alfredo http://orcid.org/0000-0001-7479-8658
Asensio-Martínez, Elena http://orcid.org/0000-0002-2539-5710
González-Moya, Manuel http://orcid.org/0000-0002-1428-2745
Carmona-Bayonas, Alberto http://orcid.org/0000-0002-1930-9660
Calderon, Caterina http://orcid.org/0000-0002-6956-9321
Funding for this research was provided by:
sociedad española de oncología médica
astrazeneca
Article History
Received: 23 July 2021
Accepted: 30 December 2021
First Online: 6 January 2022
Declarations
:
: The study was approved by the Research Ethics Committee of the Principality of Asturias (May 17, 2019) and by the Spanish Agency of Medicines and Medical Devices (AEMPS) (identification code: L34LM-MM2GH-Y925U-RJDHQ). The study has been performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. This study is an observational, non-interventionist trial.
: Signed informed consent was obtained from all patients.
: Informed consent and approval by the national competent authorities includes permission for publication and diffusion of the data.
: The authors declare no competing interests.
Free to read: This content has been made available to all.